Healthcare >> CEO Interviews >> November 6, 2000
PERCY WILLIAM CECIL LOMAX BSc (Econ) (Aged 56), is the Executive
Chairman of ReGen Therapeutics Plc. Percy Lomax joined the commercial
intelligence department of Allen & Hanbury's, part of the Glaxo Group,
in July 1967 and has been involved in the drug industry since then,
either as an adviser or an employee. He was stockbroker in August 1987
to the flotation of Medirace Plc which became Medeva Plc. As a
healthcare analyst at Flemings he worked on the second fund raising for
Wellcome in 1992. In 1995 he co-founded PolyMasc Pharmaceuticals Plc
and was instrumental in its flotation in December of the year. In 1996
he advised on the rescue rights issue of Proteus Plc and the flotation
of Oxford Biomedica Plc. Profile
ReGen Therapeutics?
Mr. Lomax: ReGen was incorporated to commercialise the intellectual
property discovered at the Ludwik
